

News Release

FOR IMMEDIATE RELEASE

February 18, 2011

Contact: **Neal G. Koller**
President & CEO
Board of Directors
+1 (443) 994-0101

PluroGen Receives & Ships 1st Austrian Order for PluroGel® with Silver Sulphadiazine

(Charlottesville, VA, 18 February 2011) – PluroGen Therapeutics, Inc. today announced that it has received and shipped its first order to its Austrian distribution partner for PluroGel® with Silver Sulphadiazine.

Neal G. Koller, President & CEO of PluroGen, commenting on the first Austrian order said “Europe is estimated at a \$2.6 billion market opportunity for PluroGen, with Austria at \$59.5 million. Austria is a significant revenue and profit opportunity for the Company. Our new Austrian distribution partner will provide a solid sales, marketing and distribution base for PluroGel® with Silver Sulphadiazine. They are an established company with long-term and excellent relationships in the Austrian physician, hospital, nursing home and pharmacy markets. We look forward to great success in Austria.”

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology platforms. The Company's primary platform is its core PluroGel® technology which provides paradigm-shifting, superior and differentiated physical, bio-impact, and multi-function products. PluroGel® is University developed and is in routine use at the University, having shown superior results on more than 10,000 patients in two different patient populations - severe burns and wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration.

PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel® branded topical antimicrobial prescription products and PluroGel® co-branded products with select commercial partners.

PluroGen's senior management, operations team, boards and principal investigators are all recognized global commercial and clinical leaders in PluroGen's target markets of burn and wound care.

For more information about PluroGen Therapeutics, Inc., visit the Company's web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. PluroGen cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc. website is not incorporated herein by reference or otherwise.